Exxel Pharma

Exxel Pharma is advancing a novel, peripherally-targeted therapeutic platform based on the inhibition of the fatty acid amide hydrolase (FAAH) enzyme to treat conditions driven by neuronal hypersensitivity. Its lead asset, EX937, is poised to enter Phase 1/1b trials for refractory chronic cough, a large market with no FDA-approved therapies. The company's strategy leverages a dual-program approach, with a second set of global FAAH inhibitors targeting central nervous system conditions like Social Anxiety Disorder and Autism Spectrum Disorder. Led by an experienced founder/CEO and a distinguished CSO, Exxel is positioned to address significant unmet needs across multiple high-value neurological and urological indications.

Novel small molecule inhibitors of the fatty acid amide hydrolase (FAAH) enzyme, designed to be peripherally-restricted to increase anandamide levels and reduce neuronal hypersensitivity without central nervous system side effects.

The refractory chronic cough space is competitive, with several biopharma companies developing novel therapies (e.g., targeting P2X3 receptors). The broader indications like migraine and neuropathic pain are crowded markets dominated by large pharma, though Exxel's unique mechanism could differentiate it if clinically validated.